Healthy Returns: Eli Lilly's chief scientific officer breaks down the latest obesity pill data
1. Eli Lilly's orforglipron passed late-stage trials for obesity treatment successfully. 2. The drug shows potential for being a cost-effective, needle-free treatment. 3. The average patient weight loss was 10.5% after 72 weeks of usage. 4. Shares rose over 4% following the positive trial results. 5. Concerns remain about side effects and discontinuation rates in some patients.